Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

Health-care companies fell as investors continued to retreat from formerly hot areas such as obesity-drug and vaccine makers. Shares of Novo Nordisk continued their slide despite reporting a ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its ...

Novo Nordisk faces a critical phase with its obesity drug Wegovy as it confronts competition from Eli Lilly and potential job ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Even though Novo Nordisk warned that copycat versions of its obesity and diabetes drugs would hurt sales in the U.S., second-quarter sales saw a 67% rise year on year. More news covers telehealth ...

Novo Nordisk experiences heightened competition from copycat versions of its Wegovy obesity drug, affecting its market share, ...

The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...

U.S.-listed shares of Novo Nordisk (NVO) rose 0.5% in early premarket trading Wednesday after the Danish drugmaker reported ...